Clinico-biochemical Correlation of the Effect of Subconjunctival Bevacizumab for Corneal Neovascularization

Agarwal, Shweta; Angayarkanni, Narayanasamy; Iyer, Geetha; Srinivasan, Bhaskar; Natarajan, Radhika; Charola, Sanket; Arumugam, Sumathi; Padmanabhan, Prema

doi:10.1097/ico.0000000000000198

Cited by 10 publications

(10 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7 However, In another study regression of corneal neovascularization was observed in 66.7% (8/12 patients). 8 So findings this study not match with our study.…”

Section: Resultscontrasting

confidence: 91%

Subconjunctival Injection

Ahmad

Mushtaq

2017

TPMJ

View full text Add to dashboard Cite

Introduction: Normally the cornea in human eye is crystalline clear membranepresent in the anterior most portion of the eyeball. Regarding the various functions of thecornea in human eye it provides protection, clear vision, refractive media the visual systemand maintains itself as an immune privileged site. Neovascularization is mostly associated withan inflammation and always indicate a state of disease. Similarly Corneal Neovascularizationcan cause Graft rejection reaction after keratoplasty the different types of anti-VEGF agentsnow are used to prevent neovascular eye diseases. These different Anti-VEGF inhibitors areLucentis, Macugen and bevacizumab/Avastin and used in case of ocular neovascularization.Objectives: To determine the efficacy of subconjuctival injection of Avastin on patients havingcorneal neovascularization following keratoplasty. Settings: Department of OphthalmologyAllied Hospital, Faisalabad and Independent University Hospital, Faisalabad. Study Duration:The duration of study was 11-02-2015 to 11-07-2015. Results: A total of 86 cases fulfilling theinclusion/exclusion criteria were enrolled to determine the efficacy of subconjuctival injectionof Avastin on patients having corneal neovascularization following keratoplasty. Discussion:Regarding the success of Keratoplasty is determined by many factors especially avascularity ofcornea after surgery. Corneal neovasculrization is disease process secondary to various ocularinsults in which growth of vessels towards central cornea occur from the limbal vascular plexus.But now a days Bevacizumab/Avastin is commonly used in Ophthalmology as “off label” drug inthe treatment of Exudative age related macular degeneration as well as in diabetic retinopathy.Conclusion: We concluded that the frequency of efficacy of subconjuctival bevacizumab ishigher in patients having corneal neovascularization after corneal transplantation.

show abstract

“…7 However, In another study regression of corneal neovascularization was observed in 66.7% (8/12 patients). 8 So findings this study not match with our study.…”

Section: Resultscontrasting

confidence: 91%

Subconjunctival Injection

Ahmad

Mushtaq

2017

TPMJ

View full text Add to dashboard Cite

show abstract

“…(Table-III However, In another study regression of corneal neovascularization was observed in 66.7% (8/12 patients). 8 So findings this study not match with our study.…”

Section: Resultscontrasting

confidence: 57%

Subconjunctival Injection Efficacy of Subconjunctival Injection of Bevacizumab (Avastin) on Corneal Neovascularization in Patients Following Keratoplasty

Ahmad¹,

Mushtaq²

2017

TPMJ

View full text Add to dashboard Cite

“…Subsequently, the same group showed that subconjunctival injection of bevacizumab (2.5 mg/0.1 ml) was more effective than the topical application in reducing corneal neovascularization. 3,16 Other studies have used either subconjunctival injection or a combination of subconjunctival injection and topical application as discussed below.…”

Section: Management Of High-risk Corneal Transplantationmentioning

confidence: 99%

Management of high-risk corneal transplantation

Zazzo

Kheirkhah

Abud

et al. 2017

Survey of Ophthalmology

123

102

View full text Add to dashboard Cite

The cornea is the most commonly transplanted tissue in medicine. The main cause of corneal graft failure is allograft rejection. The incidence of graft rejection depends on the presence of high-risk characteristics, most notably corneal neovascularization. Although corneal graft has high success rates in the absence of these risk factors, high-risk keratoplasty is associated with low success rates due to a high incidence of immune-mediated graft rejection. To improve the survival of high-risk corneal transplantation, various preoperative, intraoperative, and postoperative measures can be considered. However, the key step in the management of these grafts is the long-term use of local and/or systemic immunosuppressive agents. Although a number of immunosuppressive agents have been employed for this purpose, the results vary significantly across different studies. This is partly due to the lack of an optimized method for their use as well as the lack of a precise stratification of the degree of risk in each individual patient. New targeted biologic treatments as well as tolerance-inducing methods show promising horizons in the management of high-risk corneal transplantation in near future.

show abstract

Clinico-biochemical Correlation of the Effect of Subconjunctival Bevacizumab for Corneal Neovascularization

Abstract: Subconjunctival bevacizumab helps to regress CNV due to a decrease in corneal VEGF levels and might prove beneficial for use in clinical conditions leading to CNV.

Cited by 10 publications

References 18 publications

Subconjunctival Injection

Subconjunctival Injection

Subconjunctival Injection Efficacy of Subconjunctival Injection of Bevacizumab (Avastin) on Corneal Neovascularization in Patients Following Keratoplasty

Management of high-risk corneal transplantation

Contact Info

Product

Resources

About